Samsung to make $22bn investment in new technology

South Korea-based Samsung has revealed plans to commit W25 trillion ($22 billion) to pursue new technology in areas including biopharmaceuticals and artificial intelligence (AI).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Generic rival blocked as AZ defends diabetes stronghold

17 February 2026 With a UK defeat still fresh, the Swedish-British drugmaker has secured breathing room in Australia—but a validity battle and key question of patent law looms at trial.

Asia-Pacific

Australia boutique hires experienced life sciences litigator

23 February 2023 New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

More features

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Samsung to make $22bn investment in new technology

More on this story

Editor's picks

Editor's picks

More features